A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein

Abstract

Although a highly effective vaccine is available, the number of yellow fever cases has increased over the past 2 decades, which highlights the pressing need for antiviral therapeutics. In a high-throughput screening campaign, we identified an acetic acid benzodiazepine (BDAA) compound which potently inhibits yellow fever virus (YFV). Interestingly, while treatment of YFV-infected cultures with 2 M BDAA reduced the virion production by greater than 2 logs, the compound was not active against 21 other viruses from 14 different viral families. Selection and genetic analysis of drug-resistant viruses revealed that replacement of the proline at amino acid 219 (P219) of the nonstructural protein 4B (NS4B) with serine, threonine, or alanine conferred YFV with resistance to BDAA without apparent loss of replication fitness in cultured mammalian cells. However, replacement of P219 with glycine conferred BDAA resistance with significant loss of replication ability. Bioinformatics analysis predicts that the P219 amino acid is localized at the endoplasmic reticulum lumen side of the fifth putative transmembrane domain of NS4B, and the mutation may render the viral protein incapable of interacting with BDAA. Our studies thus revealed an important role and the structural basis for the NS4B protein in supporting YFV replication. Moreover, in YFV-infected hamsters, oral administration of BDAA protected 90% of the animals from death, significantly reduced viral load by greater than 2 logs, and attenuated virus infection-induced liver injury and body weight loss. The encouraging preclinical results thus warrant further development of BDAA or its derivatives as antiviral agents to treat yellow fever. IMPORTANCEYellow fever is an acute viral hemorrhagic disease which threatens approximately 1 billion people living in tropical areas of Africa and Latin America. Although a highly effective yellow fever vaccine has been available for more than 7 decades, the low vaccination rate fails to prevent outbreaks in at-risk regions. It has been estimated that up to 1.7 million YFV infections occur in Africa each year, resulting in 29,000 to 60,000 deaths. Thus far, there is no specific antiviral treatment for yellow fever. To cope with this medical challenge, we identified a benzodiazepine compound that selectively inhibits YFV by targeting the viral NS4B protein. To our knowledge, this is the first report demonstrating in vivo safety and antiviral efficacy of a YFV NS4B inhibitor in an animal model. We have thus reached a critical milestone toward the development of specific antiviral therapeutics for clinical management of yellow fever. Y ellow fever is a mosquito-borne hemorrhagic disease that is frequently associated with jaundice and is caused by yellow fever virus (YFV) infection (1). Vaccination with attenuated YFV-17D vaccine is the most important measurement to prevent yellow fever. The vaccine is safe, affordable, and highly effective, and a single dose of the vaccine is sufficient to confer sustained immunity and lifelong p...

Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection

“…Meanwhile, the N-terminal 125amino-acid domain of DENV NS4B was indicated to be responsible for inhibition of the immune response (25). Notably, several structurally distinct compounds have been identified to inhibit flavivirus replication by intensively targeting the TMD of NS4B (26)(27)(28)(29)(30)(31)(32). It is thus conceivable that inhibitors targeting TMD of NS4B would perturb its function, leading to the suppression of viral RNA replication.…”

Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly

“…However, nonenzymatic viral structural and nonstructural proteins have now been demonstrated to be viable targets of highly selective and potent antiviral agents, as highlighted by the FDA approval of HCV NS5A inhibitors for treatment of chronic hepatitis C (57) as well as the development of antiviral agents against distinct nonstructural proteins of many other RNA viruses (58). The genomes of all the viruses are wrapped with capsid protein(s) to form nucleocapsids.…”

A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists

“…A plasmid containing the dengue virus (DENV) serotype 2 New Guinea C strain cDNA (pACYC177-NGC-DENV-2) was a gift of Dr. Pei-Yong Shi at University of Taxis Medical Branch in Galveston (Xie et al, 2013). YFV 17D and DENV-2 virus stocks were produced by electroporation of Huh7.5 cells with in vitro transcribed RNAs from the corresponding cDNA constructs, as described previously (Guo et al, 2016). …”

“…β-actin mRNA was quantified to normalize the levels of viral RNA. Primers for YFV were as reported previously (Guo et al, 2016). Primers for DENV are as the following: forward primer 5′-CAGGCTATGGCACTGTCACGAT-3′; reverse primer 5′-CCATTTGCAGCAACACCATCTC-3′.…”